$井寺制药(IDRA)$
Idera candidate IMO-8400 likely to be failed drug, says Summer Street
Summer Street predicts Idera Pharmaceuticals' IMO-8400, a small-molecule toll-like receptor antagonist being tested as a treatment for psoriasis, will be a failed drug candidate. The firm says Idera is developing a third-generation product, IMO-9200, which indicates the company has low expectations for IMO-8400.